TD
The Toronto-Dominion Bank·Financial Services
112.56
0.617%(+0.69)
Close PriceLast Updated: — ET
52W L: $67.7552W H: $113.51
TD NEWS
wsj.com
13h ago
Canada's Big Banks Expected to Post Solid Second Quarter, But Outlook in Focus on Soft Backdrop
Soft economic conditions and greater uncertainty will take the spotlight as banks report earnings, shifting focus to credit-loss provisions.
zacks.com
14h ago
Why Toronto-Dominion Bank (TD) is a Top Dividend Stock for Your Portfolio
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Toronto-Dominion (TD) have what it takes?
gurufocus.com
19h ago
Is TD Overvalued? DCF Says Worth $86
On May 26, 2026, we conducted a DCF analysis for The Toronto-Dominion Bank (TD), which has shown impressive price performance over the past year, with a 73.2% i
seekingalpha.com
6d ago
Visible Alpha Breakdown Of Canadian Big Banks' Q2 2026 Earnings Expectations
Canada's largest banks head into fiscal Q2 2026 earnings facing a more complex macro backdrop than they did just three months ago. Visible Alpha consensus expectations show Canada's major banks are still poised to deliver resilient fiscal Q2 2026 results for the April quarter. Consensus expectations point to healthy year-over-year growth in revenue and earnings across most banks, although profitability metrics such as ROE and NIM are expected to soften sequentially.
zacks.com
6d ago
Can Toronto-Dominion (TD) Keep the Earnings Surprise Streak Alive?
Toronto-Dominion (TD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
globenewswire.com
May 18
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
PARSIPPANY, N.J. and TEL AVIV, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from the ongoing, real-world IMPACT-TD Registry, highlighting a significant gap in diagnosing tardive dyskinesia (TD) in patients with underlying mood disorders. While the findings demonstrate that most patients across all age groups experience multidimensional impact from the condition, young adults (aged 18-29, n=13) had the lowest rate of formal diagnosis (23%) despite having one of the highest rates of personal impact (85%). The data were presented at the 2026 American Psychiatric Association Annual Meeting, taking place May 16 – 20, 2026 in San Francisco, California.
